Trademark: 86104198
Word
GENEQURE
Status
Dead
Status Code
710
Status Date
Friday, December 3, 2021
Serial Number
86104198
Registration Number
4741698
Registration Date
Tuesday, May 26, 2015
Mark Type
4000
Filing Date
Tuesday, October 29, 2013
Published for Opposition
Tuesday, September 30, 2014
Cancellation Date
Friday, December 3, 2021

Trademark Owner History
uniQure IP B.V. - Original Registrant

Classifications
1 Viral assays, viral reagents, viral preparations, gene therapy assays, gene therapy reagents, gene therapy preparations, nucleic acid delivery assays, nucleic acid delivery reagents, nucleic acid delivery preparations, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors, all for non-medical research purposes
5 Viral medicines, gene therapy medicines, nucleic acid delivery medicines, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors for medical purposes all for medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing in the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; pharmaceutical preparations, vaccines, prophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapy, gene therapy and cell therapy in the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers
42 Research, product development and consultancy in the field of biotechnology, biologics, pharmaceutics, medical science, chemistry and biochemistry
44 Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders

Trademark Events
Dec 3, 2021
Cancelled Sec. 8 (6-Yr)
May 26, 2020
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
May 26, 2015
Registered-Principal Register
Jan 20, 2015
1(B) Basis Deleted; Proceed To Registration
Dec 1, 2014
Notice Of Allowance Cancelled
Jan 15, 2015
Case Assigned To Intent To Use Paralegal
Dec 1, 2014
Teas Post Publication Amendment Received
Nov 25, 2014
Noa E-Mailed - Sou Required From Applicant
Sep 30, 2014
Official Gazette Publication Confirmation E-Mailed
Sep 30, 2014
Published For Opposition
Sep 10, 2014
Notification Of Notice Of Publication E-Mailed
Aug 22, 2014
Law Office Publication Review Completed
Aug 21, 2014
Approved For Pub - Principal Register
Aug 15, 2014
Teas/Email Correspondence Entered
Aug 15, 2014
Correspondence Received In Law Office
Aug 8, 2014
Teas Response To Suspension Inquiry Received
Aug 6, 2014
Notification Of Letter Of Suspension E-Mailed
Aug 6, 2014
Letter Of Suspension E-Mailed
Aug 6, 2014
Suspension Letter Written
Jul 25, 2014
Teas/Email Correspondence Entered
Jul 25, 2014
Correspondence Received In Law Office
Jul 25, 2014
Assigned To Lie
Jul 24, 2014
Teas Response To Office Action Received
Feb 23, 2014
Notification Of Non-Final Action E-Mailed
Feb 23, 2014
Non-Final Action E-Mailed
Feb 23, 2014
Non-Final Action Written
Feb 14, 2014
Assigned To Examiner
Nov 5, 2013
New Application Office Supplied Data Entered In Tram
Nov 1, 2013
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24